# Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies

> **NCT04209933** · PHASE4 · COMPLETED · sponsor: **Xijing Hospital of Digestive Diseases** · enrollment: 240 (actual)

## Conditions studied

- Gastric Cancer
- Helicobacter Pylori Infection
- Bismuth

## Interventions

- **DRUG:** Bismuth potassium citrate containing quadruple therapy
- **DRUG:** Colloidal pectin bismuth capsules containing quadruple therapy
- **DRUG:** Colloidal pectin bismuth particles A quadruple therapy
- **DRUG:** Colloidal pectin bismuth particles B quadruple therapy

## Key facts

- **NCT ID:** NCT04209933
- **Lead sponsor:** Xijing Hospital of Digestive Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-25
- **Primary completion:** 2020-08-01
- **Final completion:** 2020-08-30
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04209933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04209933, "Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04209933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*